The lawsuit claims generic manufacturers violated federal and stateantitrust laws, consumer protection statutes, and common law, causing End-Payers –including Consumers and Third-Party Payers (“TPPs”) (e.g., entities such as insurers oremployers with self-funded prescription drug plans) to pay more than they should havefor certain generic drugs (“Named Generic Drugs”).

The “Settlement Class” or “Settlement Classes” include: “All persons and entities in each of the 50 United States (except Indiana and Ohio), as well as the District of Columbia, Puerto Rico and the U.S. Virgin Islands, that indirectly purchased, paid and/or provided reimbursement for some or all of the purchase price for any Named Generic Drugs, other than for resale, from May 1, 2009 to December 31, 2019.”

Settlements include:

Sun Pharmaceutical: $200 million Settlement with Sun Pharmaceutical Industries, Inc. (“Sun”) and Taro Pharmaceuticals U.S.A., Inc. (“Taro”) (“Sun/Taro” refers to both entities).

Apotex: Proposed Settlements provide that the Heritage Defendants will pay $10 million, and Apotex will pay $48 million, for the benefit of TPPs.

Sandoz: A Settlement totaling $275,000,000 has been reached in a class action lawsuit against Sandoz Inc. and Fougera Pharmaceuticals Inc. (“Sandoz”) and other generic manufacturers (the “Non-Settling Defendants”) about how much they paid for certain prescription generic drugs.